Abstract: A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.

Abstract: A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.

Abstract: Disclosed are a fused tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a pyrimidine-based tricyclic compound and a use thereof, and specifically, relates to a pyrimidine-based tricyclic compound and a use thereof in preparation of a drug for treating a related disease. Specifically, disclosed are a compound represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of compounds having pyridine structures or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of drugs for the treatment of related diseases. Specifically, disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a benzopyrazole compound. Specifically disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: A proteolysis targeting chimera (PROTAC), and an application thereof in preparation of a drug for treating a related disease. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a crystal of a tricyclic compound acting on CRBN protein and a preparation method therefor, specifically relating to a crystal of a compound of formula (I) and a preparation method therefor. An application of the crystal in the preparation of drugs for treating CRBN protein-related diseases is further comprised.

Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Abstract: Provided are a crystal of a tricyclic compound as shown in formula (I) or a pharmaceutically acceptable salt thereof and a preparation method therefor, and the use thereof in preparing a drug for treating PDE3- and/or PDE4-related diseases.

Abstract: A pharmaceutical composition of a tricyclic PDE3/PDE4 dual inhibitor compound and a preparation method therefor, specifically relating to a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, and use thereof

Abstract: The invention relates to a series of compounds with heterocycloalkyl, or isomers or pharmaceutically acceptable salts thereof, and to a use thereof in manufacturing a medicine of treatment CCR2/CCR5 antagonist-related diseases, specifically to a compound of Formula (I), or an isomer or pharmaceutically acceptable salt thereof.

Abstract: A crystal form of compound 1, a solvate thereof, a crystal form of the solvate thereof, and a preparation method therefor. Further comprised is an application of the crystal forms in the preparation of a medicament for treating diseases related to TNF?.

Abstract: A crystalline form of CXCR2 antagonist, such as Compound 1, is used in preparing a drug for treating CXCR2-related diseases.

Abstract: The present disclosure discloses a compound shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.

Abstract: An insulation sleeve insertion device for inserting insulating sleeves into wiring slots of a flat wire motor stator, comprising a processing panel, a feeder, a conveying mechanism comprising conveyor belts, a positioning mechanism comprising a limit ring and a positioning turntable, a guide mechanism comprising a plurality of second guide rails, a clamping mechanism comprising a drive rod, a positioning plate set, and a drive mechanism comprising a second driver, wherein the clamping mechanism is configured to insert insulating sleeves into wiring slots of the flat wire motor stator through the guide mechanism.

Abstract: Disclosed are a Crystal Form (I) of a pyrimidine sulfonamide compound and a preparation method therefor. The present disclosure relates to an application thereof in the preparation of a medicament for treating diseases related to ETA receptor antagonists.

Abstract: Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor.

Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.